In a trial of 46 adults with frequent vasovagal syncope (VVS), dual-chamber pacing with closed loop simulation (DDD-CLS) significantly reduced recurrent episodes when compared to sham DDI mode pacing.

Adults who struggled with heart disease as infants and had to be supported by extracorporeal membrane oxygenation reported positive health outcomes but lower quality of life 18 years later, according to a study published in Pediatric Critical Care Medicine.

Severely obese patients who underwent gastric bypass surgery showed favorable outcomes more than a decade later, including weight loss and remission of type 2 diabetes, a study published in the New England Journal of Medicine states.

A new JAMA: Cardiology study comparing the outcomes of percutaneous coronary intervention (PCI) in black and white patients showed no difference in one-year mortality rates, but it did shed light on other racial gaps in the cardiovascular treatment process.

The FDA has approved Abbott’s FreeStyle Libre Flash Glucose Monitoring System, the first personal continuous glucose monitor that doesn’t require finger stick calibration.

A Lousiana State University (LSU) professor has discovered a novel class of lipid-mediating molecules that could have the ability to protect the brain from stroke and other neurodegenerative diseases, a development he detailed in a recent Science Advances article.

Medtronic plc (NYSE: MDT) has received U.S. Food and Drug Administration (FDA) approval for its HeartWare(TM) HVAD(TM) System as a destination therapy for patients with advanced heart failure who are not candidates for heart transplants. The HVAD System, a left ventricular assist device or LVAD, helps the heart pump and increases the amount of blood that flows through the body.

Even though they are considered full-term, babies born at 37 to 38 gestational weeks could be more likely to have poor cardiorespiratory fitness (CRF) into young adulthood than those born later.